Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Developments study uncovered that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://ashleyc419yab9.worldblogged.com/profile